File size: 5,472 Bytes
a90c70e | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 | {
"architectures": [
"BertForSequenceClassification"
],
"attention_probs_dropout_prob": 0.1,
"bos_token_id": 0,
"classifier_dropout": null,
"dtype": "float32",
"eos_token_ids": 0,
"hidden_act": "gelu",
"hidden_dropout_prob": 0.1,
"hidden_size": 1024,
"id2label": {
"0": "1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING",
"1": "1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES",
"2": "1.3 CHEMICAL AND PHYSICAL SCIENCES",
"3": "1.4 METHODOLOGIES AND MEASUREMENTS",
"4": "1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)",
"5": "2.1 BIOLOGICAL AND ENDOGENOUS FACTORS",
"6": "2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT",
"7": "2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS",
"8": "2.4 SURVEILLANCE AND DISTRIBUTION",
"9": "2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)",
"10": "2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)",
"11": "3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING",
"12": "3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS",
"13": "3.3 NUTRITION AND CHEMOPREVENTION",
"14": "3.4 VACCINES",
"15": "3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)",
"16": "4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES",
"17": "4.2 EVALUATION OF MARKERS AND TECHNOLOGIES",
"18": "4.3 INFLUENCES AND IMPACT",
"19": "4.4 POPULATION SCREENING",
"20": "4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)",
"21": "5.1 PHARMACEUTICALS",
"22": "5.2 CELLULAR AND GENE THERAPIES",
"23": "5.3 MEDICAL DEVICES",
"24": "5.4 SURGERY",
"25": "5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES",
"26": "5.6 PSYCHOLOGICAL AND BEHAVIOURAL",
"27": "5.7 PHYSICAL",
"28": "5.8 COMPLEMENTARY",
"29": "5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)",
"30": "6.1 PHARMACEUTICALS",
"31": "6.2 CELLULAR AND GENE THERAPIES",
"32": "6.3 MEDICAL DEVICES",
"33": "6.4 SURGERY",
"34": "6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES",
"35": "6.6 PSYCHOLOGICAL AND BEHAVIOURAL",
"36": "6.7 PHYSICAL",
"37": "6.8 COMPLEMENTARY",
"38": "6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)",
"39": "7.1 INDIVIDUAL CARE NEEDS",
"40": "7.2 END OF LIFE CARE",
"41": "7.3 MANAGEMENT AND DECISION MAKING",
"42": "7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)",
"43": "8.1 ORGANISATION AND DELIVERY OF SERVICES",
"44": "8.2 HEALTH AND WELFARE ECONOMICS",
"45": "8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE",
"46": "8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)",
"47": "8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)"
},
"initializer_range": 0.02,
"intermediate_size": 4096,
"label2id": {
"1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING": 0,
"1.2 PSYCHOLOGICAL AND SOCIOECONOMIC PROCESSES": 1,
"1.3 CHEMICAL AND PHYSICAL SCIENCES": 2,
"1.4 METHODOLOGIES AND MEASUREMENTS": 3,
"1.5 RESOURCES AND INFRASTRUCTURE (UNDERPINNING)": 4,
"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS": 5,
"2.2 FACTORS RELATING TO PHYSICAL ENVIRONMENT": 6,
"2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS": 7,
"2.4 SURVEILLANCE AND DISTRIBUTION": 8,
"2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY)": 9,
"2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY)": 10,
"3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELL-BEING": 11,
"3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS": 12,
"3.3 NUTRITION AND CHEMOPREVENTION": 13,
"3.4 VACCINES": 14,
"3.5 RESOURCES AND INFRASTRUCTURE (PREVENTION)": 15,
"4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES": 16,
"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES": 17,
"4.3 INFLUENCES AND IMPACT": 18,
"4.4 POPULATION SCREENING": 19,
"4.5 RESOURCES AND INFRASTRUCTURE (DETECTION)": 20,
"5.1 PHARMACEUTICALS": 21,
"5.2 CELLULAR AND GENE THERAPIES": 22,
"5.3 MEDICAL DEVICES": 23,
"5.4 SURGERY": 24,
"5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES": 25,
"5.6 PSYCHOLOGICAL AND BEHAVIOURAL": 26,
"5.7 PHYSICAL": 27,
"5.8 COMPLEMENTARY": 28,
"5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)": 29,
"6.1 PHARMACEUTICALS": 30,
"6.2 CELLULAR AND GENE THERAPIES": 31,
"6.3 MEDICAL DEVICES": 32,
"6.4 SURGERY": 33,
"6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES": 34,
"6.6 PSYCHOLOGICAL AND BEHAVIOURAL": 35,
"6.7 PHYSICAL": 36,
"6.8 COMPLEMENTARY": 37,
"6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)": 38,
"7.1 INDIVIDUAL CARE NEEDS": 39,
"7.2 END OF LIFE CARE": 40,
"7.3 MANAGEMENT AND DECISION MAKING": 41,
"7.4 RESOURCES AND INFRASTRUCTURE (DISEASE MANAGEMENT)": 42,
"8.1 ORGANISATION AND DELIVERY OF SERVICES": 43,
"8.2 HEALTH AND WELFARE ECONOMICS": 44,
"8.3 POLICY, ETHICS AND RESEARCH GOVERNANCE": 45,
"8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)": 46,
"8.5 RESOURCES AND INFRASTRUCTURE (HEALTH SERVICES)": 47
},
"layer_norm_eps": 1e-12,
"max_position_embeddings": 512,
"model_type": "bert",
"num_attention_heads": 16,
"num_hidden_layers": 24,
"output_past": true,
"pad_token_id": 0,
"position_embedding_type": "absolute",
"problem_type": "multi_label_classification",
"transformers_version": "4.57.0",
"type_vocab_size": 2,
"use_cache": true,
"vocab_size": 30522
}
|